Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Atcor Medical Holdings Ltd Receives US FDA Clearance For SphygmoCor XCEL


Monday, 19 Nov 2012 05:30pm EST 

Atcor Medical Holdings Ltd announced that it has received US Food and Drug Administration (FDA) clearance to market its new SphygmoCor XCEL system in the United States. The application for FDA clearance was filed in July 2012. The SphygmoCor XCEL has been tailored for use by medical specialists in fields including cardiology, hypertension, nephrology (renal or kidney disease) and endocrinology (diabetes). 

Company Quote

0.09
0.0030 +3.45%
28 Jul 2014